ADCs targeting TROP2, HER2, HER3, c-MET, B7H3, and CEACAM5 are either approved or under investigation for the treatment of NSCLC, and similar agents against other targets are showing promise in SCLC patients (90). Here, ERBB2 is linked to non-small cell lung carcinoma.